Phase 2 trial results show XProâ„¢ benefits cognition in certain early Alzheimer's patients, pending further data analysis and FDA designation. INmune Bio Inc. announced results from its Phase 2 MINDFuL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results